Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice

Vaccine

Volumn 27, Issue 49, 2009, Pages 6905-6909

  Verma, Shailendra Kumar ^a   Kumar, Subodh ^a   Gupta, Nimesh ^a   Vedi, Satish ^b   Bhattacharya, Shailja Misra ^b   Lakshmana Rao, P V ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antibody isotyping; Cytokine profiling; Japanese encephalitis virus envelope protein domain III; Neutralizing antibody

Indexed keywords

ANTIBODY; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 2; JAPANESE ENCEPHALITIS VIRUS ENVELOPE PROTEIN DOMAIN III; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CELL ASSAY; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; JAPANESE ENCEPHALITIS VIRUS; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; RECEPTOR BINDING; SPLEEN CELL; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL PROLIFERATION; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; TH1 CELLS; VIRAL ENVELOPE PROTEINS;

EID: 70350567164     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.006     Document Type: Article

References (38)

1. Shope R.E. Medical significance of togaviruses: an overview of diseases caused by togaviruses in man and in domestic and wild vertebrate animals. In: Schlesinger R.W. (Ed). The togaviruses (1980), Academic Press, New York 47-82
2. Monath T.P. Pathobiology of the flaviviruses. In: Schlesinger S., and Schlesinger M.J. (Eds). The Togaviridae and Flaviviridae (1986), Plenum Press, New York 375-440
3. Scherer W.F., Moyer J., Izumi T., Gresser I., and McCown J. Ecologic studies of Japanese encephalitis virus in Japan: VI. swine infection. Am J Trop Med Hyg 8 (1959) 698-706
4. Konno J., Endo K., Agatsuma H., and Ishida N. Cyclic outbreaks of Japanese encephalitis among pigs and humans. Am J Epidemiol 84 2 (1966) 292-300
5. Oya A. The role of mammals as primary and supplementary hosts. Jpn J Med Sci Biol 20 Suppl. (1967) 26-30
6. Japanese encephalitis vaccines. Wkly Epidemiol Rec 73 44 (1998) 337-344
7. Hoke C.H., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Lnnis B.L., et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 (1988) 608-614
8. Ueba N., Kimura T., Nakajima S., Kurimura T., and Kitaura T. Field experiments on live attenuated Japanese encephalitis virus vaccine for swine. Biken J 21 (1978) 95-103
9. Xin Y.Y., Ming Z.G., Peng G.Y., Jian A., and Min L.H. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 39 (1988) 214-217
10. Ku C.C., King C.C., Lin C.Y., Hsu H.C., Chen L.Y., Yueh Y.Y., et al. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J Med Virol 44 (1994) 122-131
11. Monath T.P., Heinz F.X., and Flaviviruses. In: Fields B.N. (Ed). Virology vol. 1 (1996), Lipincott-Raven, Philadelphia 961-1034
12. Liu Z.L., Hennessy S., Strom B.L., Tsai T.F., Wan C.M., Tang S.C., et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26, 239 subjects. J Infect Dis 176 (1997) 1366-1369
13. Hennessy S., Liu Z., Tsai T.F., Stron B.L., Wan C.M., Liu H.L., et al. Effectiveness of live attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347 (1996) 1583-1586
14. Nothdurft H.D., Jelinek T., Marschang A., Maiwald H., Kapaun A., and Loscher T. Adverse reactions to Japanese encephalitis vaccine in travellers. J Infect 32 (1996) 119-122
15. Poland J.D., Cropp C.B., Craven R.B., and Monath T.P. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 161 (1990) 878-882
16. Sakaguchi M., Yoshida M., Kuroda W., Harayama O., Matsunaga Y., and Inouye S. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 15 (1997) 121-122
17. Juang R.F., Okuno Y., Fukunaga T., Tadano M., Fukai K., Baba K., et al. Neutralizing antibody responses to Japanese encephalitis vaccine in children. Biken J 26 (1983) 25-34
18. Kolaskar A.S., and Kulkarni-Kale U. prediction of three-dimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus. Virology 261 (1999) 31-42
19. Lin C.W., and Wu S.C. A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining site. J Virol 77 (2003) 2600-2606
20. Rey F.A., Heinz F.X., Mandl C., Kunz C., and Harrision S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375 (1995) 291-298
21. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75 (2001) 7769-7773
22. Cecilia D., and Gould E.A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 181 (1991) 70-77
23. Seif S.A., Morita K., Matsuo S., Hasebe F., and Igarashi A. Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine 13 (1995) 1515-1521
24. Wu S.C., Lian W.C., Hsu L.C., and Liau M.Y. Japanese encephalitis virus antigenic variants with characteristics differences in neutralization resistance and mouse virulence. Virus Res 51 (1997) 173-181
25. Verma S.K., Gupta N., Pattnaik P., Babu J.P., Rao P.V.L., and Kumar S. Antibodies against refolded recombinant envelope protein (domain III) of Japanese encephalitis virus inhibit the JEV infection to porcine stable kidney cells. Protein Peptide Lett 16 (2009) 1334-1341
26. Misra S., Mukherjee M., Dixshit M., and Chaterjee R.K. Cellular response of Mastomys and gerbil in experimental filariasis. Trop Med Int Health 3 2 (1998) 124-129
27. Mosmann T.R., and Fong T. Specific assays for cytokine production by T-cells. J Immunol Methods 116 (1989) 151-158
28. Mason P.W., Dalrymple J.M., Gentry M.K., McCown J.M., Hoke C.H., Burke D.S., et al. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 70 pt8 (1989) 2037-2049
29. Wu S.C., Yu C.H., Lin C.W., and Chu I.M. The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuventicity. Vaccine 21 (2003) 2516-2522
30. Alka, Bharati K., and Malik Y.P.S. Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med Microbiol Immunol 196 (2007) 227-231
31. Roitt I., Brostoff J., and Male D. Immunology. 6th ed (2001), Mosby Publications, London
32. Zhou A., Paranjape J.M., Der S.D., Williams B.R., and Silverman R.H. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 2 (1999) 435-440
33. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., et al. Immune response in mice that lack the interferon-gamma receptor. Science 5102 (1993) 1742-1745
34. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 20 (2000) 9580-9585
35. Shi Y.J., Jiang Z.Y., and Zeng K. Effect of IL-6 and TNF-alpha on Dengue virus infection of human dendritic cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 4 (2006) 469-471
36. Flint S.J., Enquist L.W., Racaniello, and Skalka A.M. Principles of virology, molecular biology, pathogenesis, and control of animal viruses (2000), ASM Press p. 531-594
37. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
38. Borish L., and Rosenwasser L.J. Update on cytokines. J Allergy Clin Immunol 3 (1996) 719-733